RE:EXECUTIVE INTERVIEW – a lot of information here
one of the strong points;
Your team is exploring HLA-typing? What can that offer patients?
A: HLA typing offers the chance to have patients treated with Bria-OTS, which will be personalized and tailored to induce to most potent immune response against the cancer. But the cell lines used will be pre-manufactured and stored in the frozen state, which offers the convenience of an off-the-shelf therapy. Contrast this with the recently developed CAR-T therapy. This therapy requires that patients have white blood cells removed and then manipulated in tissue culture, and then infused back into the patient. This process takes approximately a month, is very expensive, and has to be repeated for each treatment. The same is true for Provenge (mentioned earlier). Or approach circumvents these logistical and cost problems by using cell lines that grow easily in tissue culture at low cost and are premanufactured. The HLA typing personalizes the process, so you still get an immune response tailored to the patient.